NCT04993014View on ClinicalTrials.gov

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2028

Conditions
Breast NeoplasmsHER2-positive Breast CancerCirculating Tumor Cell
Interventions
DRUG

Pertuzumab

Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)

DRUG

Trastuzumab

Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts

OTHER

Circulating tumor cells

Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.

Trial Locations (1)

01525-001

RECRUITING

A.C. Camargo Cancer Center, São Paulo

All Listed Sponsors
lead

AC Camargo Cancer Center

OTHER